Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer

Global Heart Hub and Novartis announced the launch of the Invisible Nation program. Invisible Nation will bring together a worldwide network of patient organizations and other stakeholders in the cardiovascular (CV) space committed to effecting systemic change in the management of atherosclerotic cardiovascular disease (ASCVD). The program aims to prevent many of the 15 million […]

Continue Reading

Petrovax Pharm is taking part in the international pharmaceutical exhibition CPhI Worldwide-2021

Petrovax Pharm, the Russian biopharmaceutical company, will participate in CPhI Worldwide-2021 – the international specialized pharmaceutical industry exhibition. This year, it will be held from 9 to 11 November in Italy (Milan) on the territory of the largest exhibition complex Fiera Milano. At the exhibition stand, Petrovax Pharm will present own original pharmaceutical products, that […]

Continue Reading

Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, […]

Continue Reading

Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations

Interim results from the first co-administration descriptive study of Sanofi’s Fluzone® High-Dose Quadrivalent vaccine with Moderna’s COVID-19 mRNA investigational booster dose show that the administration of the vaccines at the same visit had similar immunogenicity responses and a similar safety and tolerability profile compared to each vaccine administered individually. Fluzone® High-Dose Quadrivalent is a high-dose […]

Continue Reading

Pfizer and BioNTech receive CHMP positive opinion for COVID-19 vaccine booster in the European Union

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies’ COVID-19 vaccine as a booster dose at least six months after the second dose in individuals […]

Continue Reading

Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly reduces viral load in patients hospitalised with COVID-19

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospitalised with COVID-19. The trial met its primary endpoint, showing that Ronapreve significantly reduced viral load within seven days of treatment in patients who had not mounted a natural antibody response of […]

Continue Reading

Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate

Recent positive interim results of Sanofi’s mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company’s platform robust capabilities and strategy in mRNA. Taking into account public health needs and given sufficient mRNA COVID-19 vaccines supply can be expected going forward, Sanofi has decided not to pursue the development of its COVID-19 mRNA candidate into […]

Continue Reading